Publications by authors named "Daniel P Rossignol"

Claim this Profile
T
The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
Kari Ann Shirey, Wendy Lai, Alison J Scott, Michael Lipsky, Pragnesh Mistry, Daniel P Rossignol

Nature· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Steven M Opal, Pierre-Francois Laterre, Bruno Francois, Steven P LaRosa, Derek C Angus, Daniel P Rossignol

JAMA· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.
Naoki Aikawa, Yoshio Okubo, Melvyn Lynn, Daniel P Rossignol, Y Nancy Wong

Innate Immun· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Monica Mita, Kevin R Kelly, Alain Mita, Alejandro D Ricart, Ofelia Romero, Daniel P Rossignol

Clin Cancer Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Daniel P Rossignol, Nancy Wong, Robert Noveck, Melvyn Lynn

Innate Immun· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.
Kishor M Wasan, Verica Risovic, Olena Sivak, Stephen D Lee, Douglas X Mason, Daniel P Rossignol

Pharm Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
Elliott Bennett-Guerrero, Hilary P Grocott, Jerrold H Levy, Kevin A Stierer, Charles W Hogue, Daniel P Rossignol

Anesth Analg· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR4 antagonists for endotoxemia and beyond.
Daniel P Rossignol, Melvyn Lynn

Curr Opin Investig Drugs· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of endotoxin response by synthetic TLR4 antagonists.
Lynn D Hawkins, William J Christ, Daniel P Rossignol

Curr Top Med Chem· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
Daniel P Rossignol, Kishor M Wasan, Eugene Choo, Edwin Yau, Nancy Wong

Antimicrob Agents Chemother· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, Richard J Kao, Carlos A Perdomo, Daniel P Rossignol

J Pharmacol Exp Ther· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
Kishor M Wasan, Olena Sivak, Richard A Cote, Aaron I MacInnes, Kathy D Boulanger, Daniel P Rossignol

Antimicrob Agents Chemother· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
Daniel P Rossignol, Melvyn Lynn

J Endotoxin Res· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
Maureen Mullarkey, Jeffrey R Rose, John Bristol, Tsutomu Kawata, Akufumi Kimura, Daniel P Rossignol

J Pharmacol Exp Ther· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
Melvyn Lynn, Daniel P Rossignol, Janice L Wheeler, Richard J Kao, Carlos A Perdomo

J Infect Dis· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
Lynn D Hawkins, Sally T Ishizaka, Pamela McGuinness, Huiming Zhang, Wendy Gavin, Daniel P Rossignol

J Pharmacol Exp Ther· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis